Chemoinformaics analysis of (E)-DODEC-2-EN-1-OL
| Molecular Weight | 184.323 | nRot | 9 |
| Heavy Atom Molecular Weight | 160.131 | nRig | 1 |
| Exact Molecular Weight | 184.183 | nRing | 0 |
| Solubility: LogS | -3.698 | nHRing | 0 |
| Solubility: LogP | 3.868 | No. of Aliphatic Rings | 0 |
| Acid Count | 0 | No. of Aromatic Rings | 0 |
| Base Count | 0 | No. of Aliphatic Carbocycles Rings | 0 |
| Atoms Count | 37 | No. of Aliphatic Hetero Cycles | 0 |
| No. of Heavy Atom | 13 | No. of Aromatic Carbocycles | 0 |
| nHetero | 1 | No. of Aromatic Hetero Cycles | 0 |
| nBridge Head | 0 | No. Saturated Carbocycles | 0 |
| No. of Hydrogen atom | 24 | No. of Saturated Hetero Cycles | 0 |
| No. of Carbon atom | 12 | No. of Saturated Rings | 0 |
| No. of Nitrogen atom | 0 | No. of Arom Atom | 0 |
| No. of Oxygen atom | 1 | No. of Arom Bond | 0 |
| nHA | 1 | APOL | 36.845 |
| nHD | 1 | BPOL | 24.077 |
| QED | 0.471 |
| Synth | 2.479 |
| Natural Product Likeliness | 0.774 |
| NR-PPAR-gamma | 0.003 |
| Lipinski | Accepted |
| Pfizer | Rejected |
| GSK | Accepted |
| Golden Triangle | Rejected |
| Pgp-inh | 0.005 |
| Pgp-sub | 0.001 |
| HIA | 0.003 |
| CACO-2 | -4.258 |
| MDCK | 0.0000268 |
| BBB | 0.873 |
| PPB | 0.686583 |
| VDSS | 1.093 |
| FU | 0.260121 |
| CYP1A2-inh | 0.961 |
| CYP1A2-sub | 0.476 |
| CYP2c19-inh | 0.716 |
| CYP2c19-sub | 0.819 |
| CYP2c9-inh | 0.639 |
| CYP2c9-sub | 0.425 |
| CYP2d6-inh | 0.026 |
| CYP2d6-sub | 0.123 |
| CYP3a4-inh | 0.128 |
| CYP3a4-sub | 0.321 |
| CL | 11.029 |
| T12 | 0.328 |
| hERG | 0.036 |
| Ames | 0.007 |
| ROA | 0.055 |
| SkinSen | 0.604 |
| Carcinogencity | 0.128 |
| EI | 0.981 |
| Respiratory | 0.428 |
| NR-Aromatase | 0.008 |
| Antiviral | No |
| Prediction | 0.536767 |